Search Results
Your search for ,aGe matches 8736 pages
Showing 5851 - 5900With an Illustrious Career in Breast Oncology, Daniel F. Hayes, MD, FASCO, Follows in the Footsteps of Giants as ASCO President-Elect
ASCO President-Elect Daniel F. Hayes, MD, FASCO, was born in Shelbyville, Indiana, a small city in the center of the state. “My dream was to become a high school basketball and track and field coach; my older brother wanted to be a doctor, and his ambitions also began in first grade,” revealed Dr....
Monitoring Survivors of Childhood Cancers for Late Effects of Treatment
This past January, ASCO held its inaugural Cancer Survivorship Symposium, which brought together the fields of medical oncology and primary care to address the critical need for coordinated care for cancer survivors. Among the presenters at the symposium was Smita Bhatia, MD, MPH, who gave the...
Occupational Therapy for Adults With Cancer: An Unmet Need
Adults with cancer are at high risk for functional limitations that would negatively affect their quality of life. Occupational therapy offers a range of supportive services, with the specific goal of helping these patients engage in life as independently as possible. To provide a better...
ASCO Past-President Anticipates a New Position With an Ongoing Goal of Advancing the Field of Oncology
After an extensive national search, Hartford HealthCare has appointed ASCO Past-President Peter Paul Yu, MD, FACP, FASCO, as the first Physician-in-Chief of the Hartford HealthCare Cancer Institute. As Physician-in-Chief, Dr. Yu will be responsible for working closely and collaboratively with...
Eribulin Improves Overall Survival vs Dacarbazine in Previously Treated Advanced Liposarcoma or Leiomyosarcoma
In a phase III trial reported in The Lancet, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven Cancer Institute, Belgium, and colleagues found that eribulin (Halaven) improved overall survival vs dacarbazine in patients with advanced or metastatic soft-tissue sarcoma who had received...
Anti–PD-L1 Antibody Atezolizumab Active in Previously Treated Advanced Urothelial Carcinoma
In a phase II trial reported in The Lancet, Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that the anti–PD-L1 (programmed cell death ligand 1) antibody atezolizumab produced durable responses in a marked proportion of patients with previously treated...
No Survival Benefit Reported With Chemoradiotherapy vs Continued Chemotherapy in Controlled Locally Advanced Pancreatic Cancer
In the phase III GERCOR LAP07 trial reported by Pascal Hammel, MD, of Beaujon Hospital, Clichy, France, and colleagues in JAMA, there was no survival benefit of chemoradiotherapy vs continued chemotherapy in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine...
Neratinib Improves Invasive Disease–Free Survival in HER2-Positive Breast Cancer
In the phase III ExteNET trial reported in The Lancet Oncology, Arlene Chan, MD, of the Breast Cancer Research Centre-Western Australia, Perth, and colleagues found that 1 year of treatment with the HER1, HER2, and HER4 tyrosine kinase inhibitor neratinib improved invasive disease–free survival...
Is Male Breast Cancer Overlooked in Clinical Trials?
Three and a half years ago, Oliver Bogler, PhD, a cancer biologist and Senior Vice President of Academic Affairs at the University of Texas MD Anderson Cancer Center, saw his personal and professional worlds collide. He received a cancer diagnosis—one that mirrored his wife’s. “Some might say that ...
Young Women Require Formal Assessment to Identify Breast Cancer Risk
Half of the young women presenting to an academic surgical breast practice would qualify for mammography screening starting at age 40. According to the newly updated guidelines, these young at-risk women may be missed, researchers reported at the 2016 American Society of Breast Surgeons (ASBS)...
Relatives of Patients With Carcinoma of Unknown Primary at Increased Risk for This and Other Cancers
Relatives of patients with carcinoma of unknown primary are at increased risk of developing this type of cancer themselves and several other malignant neoplasms, including lung, pancreatic, and colon cancers; non-Hodgkin lymphoma; and myeloma, according to a study published in JAMA Oncology. “Some...
Significant Increased Risk of Noncancer Hospitalization Following Diagnosis of Prostate Cancer in the Elderly
Elderly men had a significant increase in the risk of noncancer hospitalizations following the diagnosis of prostate cancer, according to a population-based retrospective cohort study conducted by Amit D. Raval, PhD, and colleagues at West Virginia University, Morgantown. Results were published in...
Expect Questions About the New Rule on E-Cigarettes
“There are a lot of myths around new and emerging tobacco products, including e-cigarettes, and unfortunately, the biggest misconception is that these products are fairly or entirely harmless and risk-free,” Alexander V. Prokhorov, MD, PhD, said in an interview with The ASCO Post about a new...
New FDA Rule Prohibits Sale of E-Cigarettes to Anyone Under Age 18 and Requires Warning Labels
A new rule extending U.S. Food and Drug Administration (FDA) oversight to all tobacco products, including electronic cigarettes (e-cigarettes), and banning the sale of these products to anyone under the age of 181 was hailed as a major advanced by many leaders of medical and health organizations....
Highlights From the 2016 AACR Annual Meeting
This year’s Annual Meeting of the American Association for Cancer Research (AACR) featured outstanding research in the field of cancer, as well as an inspiring talk by Vice President Joe Biden (see the May 10 issue of The ASCO Post). Here are some summaries of studies that warrant attention; they...
Cabozantinib in Advanced Renal Cell Carcinoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 25, 2016, a tablet formulation of cabozantinib...
$3 Million NCI Grant Awarded to Study Links Between Liver Cancer and HIV
Vincent Lo Re, MD, MSCE, Assistant Professor of Medicine in the Division of Infectious Diseases and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania, and Amy Justice, MD, PhD, Professor of General Medicine and Public Health at Yale School of Public Health, have been ...
Characterization of Molecular Differences in Cancer Between Male and Female Patients
It is well known that men and women differ in terms of cancer susceptibility, survival, and mortality, but exactly why this occurs at a molecular level has been poorly understood. A study at The University of Texas MD Anderson Cancer Center reviewed 13 cancer types and provided a molecular...
Venetoclax Produces High Response Rate in Relapsed or Refractory CLL With 17p Deletion
In a phase II study reported in The Lancet Oncology, Stilgenbauer et al found that the BCL2 inhibitor venetoclax (Venclexta) produced a high response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) with the 17p deletion (del [17p]). The study supported the recent...
ASCO 2016: Autologous Stem Cell Transplant Remains Relevant in Multiple Myeloma, Even in Era of Novel Agents
Early findings from a phase III clinical trial (EMN02/HO95 MM) showed that patients with multiple myeloma who received an autologous stem cell transplant survived longer without disease progression than those who received only chemotherapy using novel agents. This is the largest study reported to...
ATS 2016: Untreated Severe Obstructive Sleep Apnea Associated With Increased Aggressiveness of Cutaneous Melanoma
Untreated severe obstructive sleep apnea is associated with increased aggressiveness of malignant cutaneous melanoma, according a multicenter, prospective study. The new study, which involved researchers from 24 teaching hospitals that are part of the Spanish Sleep and Breathing Network, was...
Adding Bevacizumab to Letrozole Improves Progression-Free Survival but Increases Toxicity in Metastatic Breast Cancer
The addition of bevacizumab (Avastin) to first-line endocrine therapy with letrozole improved progression-free survival but increased toxicity among postmenopausal women with hormone receptor–positive metastatic breast cancer, according to the results of the phase III CALGB 40503/Alliance...
No Survival Benefit Reported With Chemoradiotherapy vs Continued Chemotherapy in Controlled Locally Advanced Pancreatic Cancer
In the phase III GERCOR LAP07 trial reported in JAMA by Hammel et al, there was no survival benefit of chemoradiotherapy vs continued chemotherapy in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib (Tarceva). Study Details In...
Addition of Ixazomib to Lenalidomide/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
Moreau et al found that adding the oral proteasome inhibitor ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone significantly prolonged progression-free survival among patients with relapsed, refractory, or relapsed and refractory multiple myeloma. They reported the findings from the...
Study of SEER Data Identifies Racial/Ethnic Disparities in Survival in Patients With Young-Onset Colorectal Cancer
In a study of Surveillance, Epidemiology, and End Results (SEER) data reported in the Journal of Clinical Oncology, Holowatyj et al found that survival was significantly poorer in black vs white patients diagnosed with colorectal cancer between the ages of 20 and 49 years. Study Details The...
AUA 2016: Relationship Between Testosterone Therapy and Prostate Cancer Explored
Men with low levels of the male sex hormone testosterone need not fear that testosterone replacement therapy will increase their risk of prostate cancer. This is the finding of an analysis of more than a quarter-million medical records of mostly white men in Sweden, research led by investigators at ...
Some Diagnostic Variability in Interpreting Breast Biopsy Slides
Pathologists disagree about 8% of the time when interpreting a single breast biopsy slide, with more overinterpretation than underinterpretation in discordant cases, according to an analysis combining results from the B-Path (Breast Pathology) study with data on the prevalence of breast cancer...
Improved Survival With Shorter Delays Between Diagnosis and Surgery and Before Initiating Adjuvant Chemotherapy
The survival benefits of reducing the time to surgery following a diagnosis of breast cancer and the time to initiation of adjuvant chemotherapy following surgery were outlined in two articles and an accompanying editorial in JAMA Oncology. Analyzing two independent population-based studies with a...
Corporate Angel Network’s 50,000th Patient Flight Benefits Young Retinoblastoma Patient
On April 14, 2016, an 18-month-old patient with cancer named Baron Yerby flew home to Atlanta after receiving treatment at Memorial Sloan Kettering Cancer Center. However, instead of flying on a crowded commercial plane with the potential for immune deficiency issues, he and his parents flew on a...
FDA Launches First Campaign Focused on Dangers of Smokeless Tobacco Among Rural Teens
The U.S. Food and Drug Administration (FDA) has announced it is expanding its award-winning “The Real Cost” campaign to educate rural white male teenagers about the negative health consequences associated with smokeless tobacco use. For the first time, messages on the dangers of smokeless tobacco...
Expert Point of View: Julie Margenthaler, MD and Mahmoud El-Tamer, MD
Press briefing moderator Julie Margenthaler, MD, of Washington University Siteman Cancer Center, St. Louis, who is Communications Committee Chair for the American Society of Breast Surgeons, agreed that surveillance would be acceptable only within a clinical trial, and one is underway now....
AUA 2016: Cell-Cycle Progression Score Provides Significant Prognostic Information in Patients With Gleason Score < 7
Myriad Genetics announced results from a study of the prognostic information provided by its Prolaris test in patients with prostate cancer and a Gleason score < 7 at the 111th Annual Scientific Meeting of the American Urological Association (AUA) (Abstract MP02-20). Prolaris is a novel 46-gene ...
AUA 2016: BRCA Gene Mutations Associated With Increased Prostate Cancer Risk
Though predominantly known for their increased associations with breast cancer risk, germline mutations in the BRCA1 and BRCA2 genes are also associated with an increased susceptibility to other diseases, including prostate cancer. New data being presented during the 111th Annual Scientific Meeting ...
Risk Factors for Acute Pancreatitis in Children/Young Adults With Acute Lymphoblastic Leukemia
In a study reported in the Journal of Clinical Oncology, Liu et al found that Native American ancestry, older age, higher cumulative dose of asparaginase, and a rare variant of the CPA2 gene increased risk for pancreatitis in children/young adults with acute lymphoblastic leukemia (ALL). Study...
New JOP Articles Highlight the Impact of NCI Programs on Clinical Trial Enrollment
Two new original contributions in the Journal of Oncology Practice (JOP) highlight how National Cancer Institute (NCI) programs have impacted clinical trial enrollment. The first1 looked at the pilot phase of the NCI’s Community Cancer Centers Program (NCCCP) and found that trial availability and...
Defibrotide Sodium for Hepatic Veno-occlusive Disease After HSCT
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 30, 2016, defibrotide sodium (Defitelio) was approved for...
Roundup of Ovarian Cancer Abstracts From 2016 SGO Annual Meeting on Women’s Cancer
At the 2016 Society of Gynecologic Oncology’s (SOG’s) Annual Meeting on Women’s Cancer, Thomas J. Herzog, MD, Clinical Director, University of Cincinnati (UC) Cancer Institute and Professor of Obstetrics and Gynecology at UC College of Medicine, provided commentary on several noteworthy ovarian...
Intraperitoneal Chemotherapy in Question in Ovarian Cancers
A phase III trial of bevacizumab (Avastin) with intravenous vs intraperitoneal chemotherapy showed no improvement in progression-free survival for first-line treatment of patients with optimally surgically resected stage II and III ovarian, peritoneal, or fallopian tube cancer.1 When compared with...
Selected Abstracts From the 2016 BMT Tandem Meetings
The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research and the American Society of Blood and Marrow Transplantation. Held recently in Honolulu, Hawaii, this year’s BMT Tandem Meetings drew 3,000 attendees from 35 countries,...
CancerCare Issues Report on Nationwide Surveys of 3,000 People Diagnosed With Cancer
The national nonprofit organization CancerCare has announced the publication of a comprehensive report on experiences, perceptions, and needs of people who are living with and beyond a cancer diagnosis. The 2016 CancerCare Patient Access and Engagement Report is a compilation of results from six...
One-Third of Patients With Advanced Melanoma Survive at Least 5 Years After Nivolumab Treatment
The news is good from the longest follow-up survival study of patients with advanced melanoma who were treated with the anti–programmed cell death protein 1 (PD-1) agent nivolumab (Opdivo).1 Thirty-four percent of patients who received the drug in a phase I trial (CA909-003) were alive 5 years...
Study Finds Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals
As reported by Vasen et al in the Journal of Clinical Oncology, surveillance for pancreatic ductal adenocarcinoma in high-risk individuals appears to be of benefit in individuals at risk due to CDKN2A mutation, with the advantage being less clear among individuals at risk due to familial clustering ...
Similar Outcomes Reported With ABVD vs BEACOPP in High-Risk Advanced Hodgkin Lymphoma
In a phase III trial (EORTC 20012 Intergroup Trial) reported by Carde et al in the Journal of Clinical Oncology, similar outcomes were achieved with eight cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) vs four cycles each of escalated BEACOPP (bleomycin, etoposide, doxorubicin,...
Study Finds Cancer Mortality Risks From Long-Term Exposure to Ambient Fine Particulate Matter
Long-term exposure to ambient fine particulate matter, a mixture of environmental pollutants, was associated with increased risk of mortality for many types of cancer in an elderly Hong Kong population, according to a study published by Wong et al in Cancer Epidemiology, Biomarkers &...
ESTRO 2016: SBRT in Early-Stage Lung Cancer Linked to Increased Risk of Noncancer Deaths
Researchers have found that treating patients who have early-stage non–small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) is associated with a small but increased risk of death from causes other than cancer, according to findings presented at the European Society...
ESTRO 2016: Radiation and L19-IL2 Immunotherapy Combination Shows Activity in Preclinical Models
Radiation therapy not only targets and destroys cancer cells, but also helps to activate the immune system against their future proliferation. However, this immune response is often not strong enough to be able to completely eradicate tumors, and even when it is, its effect is limited to the area...
Study Finds No Association Between Anthracycline-Based Chemotherapy and Cognitive Decline in Women With Breast Cancer
A new study by University of California, Los Angeles (UCLA) researchers published by Van Dyk et al in JAMA Oncology found that commonly used chemotherapy drugs showed no association with cognitive decline following treatment in women with breast cancer. The report addresses recent concerns that the ...
Canadian Study Suggests Increased Risk of Cardiac Dysfunction With Trastuzumab-Based Regimens for Breast Cancer
In a Canadian retrospective population-based cohort study reported in the Journal of Clinical Oncology, Thavendiranathan et al found that trastuzumab (Herceptin)-based regimens were associated with an increased risk of treatment-related cardiac dysfunction among women with breast cancer, with an...
Solid Organ Transplant Recipients With Preexisting Malignancies in Remission May Be More Likely to Die, Develop New Cancers
Patients who had cancer before receiving an organ transplant were more likely to die of any cause, die of cancer, or develop a new cancer than organ recipients who did not previously have cancer, a new study published by Acuna et al in the journal Transplantation has found. However, the increased...
Advantage of Afatinib vs Gefitinib in First-Line Treatment of EGFR-Mutant NSCLC
The irreversible ErbB family inhibitor afatinib (Gilotrif) was associated with improvement in progression-free survival and time to treatment failure vs the reversible EGFR (epidermal growth factor receptor) inhibitor gefitinib (Iressa) in the first-line treatment of EGFR-mutant non–small...
